Sustainability has been a major issue within Lavetan for many years. In 2022, Lavetan launched a charter, a three-year plan to progressively embed the 17 United Nations (UN) Sustainable Development Goals (SDGs) into the company. So far, several goals have been achieved and plans developed for next year. An in-house Lavetan sustainability team has also been set up. Katrijn Verbeek, Scientific Manager at Lavetan, discusses the approach.

Our colleague, Axel Haack, was given the great opportunity to showcase the GBA Group Pharma laboratories and secondly he visited GBA Pharma Labs (part 2/5).

In January 2021 a new standard, ISO 10993-23, covering tests for irritation was issued that prescribes the use of in vitro test methods before considering any in vivo tests, all to fulfil the 3R principle of replacement, reduction, and refinement of animal tests.

Leen Van Campenhout started her new position as the new nutritional science manager at Lavetan on the first of October. She is a bioengineer with a passion for industrial microbiology. Leen brings broad professional expertise: from business to education. Her move to Lavetan offers an exciting mix of microbiology and education. She now focuses on team coaching and training development and deployment We spoke with her about her background and ambitions.

With the acquisition of the Swedish company Key2Compliance AB, GBA Group is expanding its range of consulting and training services for the medical device, In Vitro Diagnostics (IVD), and pharmaceutical industry. GBA Group is thus taking another important step towards establishing itself as a broad service provider for international customers in this area.